Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease by Cha, Sungho et al.
INTRODUCTION
Kawasaki disease (KD) is an acute inflammatory illness
that affects young children and is characterized by persistent
fever, various kinds of rashes, conjunctivitis, inflammation
of mucous membranes, swollen erythematous hands and feet,
and cervical lymphadenopathy (1, 2). The cause of KD is
unknown; epidemiologic data suggest it may be an infec-
tious agent, but intensive searches for such an agent have
been unsuccessful. The use of intravenous immunoglobulin
(IVIG) with aspirin is standard treatment and in most patients
diminishes inflammation and vasculitis rapidly enough to
prevent the development of coronary artery lesions (3). Coro-
nary artery abnormalities such as aneurysms or ectasia devel-
op in 3-5% of patients following treatment with IVIG and
high-dose aspirin (4, 5). Without proper treatment, coro-
nary artery aneurysms or ectasia develop in approximately
15% to 25% of affected children (6, 7). The administration
of high-dose IVIG reduces both the duration of fever and the
incidence of coronary artery aneurysms, but approximately
10-20% of patients have persistent or recurrent fever despite
IVIG (8, 9). Some clinicians advocate re-treatment with
IVIG or administration of pulsed steroids in children with
persistent and recurrent fever or worsening echocardiogra-
phy (8, 9). We retrospectively analyzed all children admit-
ted with KD to determine the occurrence and variables asso-
ciated with the initial IVIG treatment failure, and catego-
rized differences in clinical characteristics between respon-
ders and nonresponders to initial IVIG treatment.
MATERIALS AND METHODS
Subjects
Patients who were admitted to the Department of Pedi-
atrics, Kyung Hee University Hospital, Seoul, Korea between
March 1995 and April 2004 and who satisfied the criteria
for KD (10) were enrolled in this study. We included patients
whose fever persisted more than 3 days who met other crite-
ria, even though they did not meet all the clinical criteria
initially. Our laboratory workup for patients with KD was a
routine, retrospective laboratory analysis. All patients were
initially treated with 2 g/kg IVIG during a 10-12 hr period,
and aspirin (80-100 mg/kg/day in divided doses) was admin-
istered until the second week of treatment or until the fever
subsided, after which it was reduced to 3-5 mg/kg/day.
Patients were classified into two groups. Group A includ-
ed patients who received a single dose of IVIG treatment and
responded (defined as defervescence by 48 hr after IVIG and
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Treatment in Kawasaki Disease
The aims of this study were to determine the occurrence and variables associated
with the initial intravenous immunoglobulin (IVIG) treatment failure in Kawasaki
disease (KD) and to categorize differences in clinical characteristics between respon-
ders and nonresponders to initial IVIG treatment. Patients were classified into two
groups. Group A included 33 patients who received a single dose of IVIG treatment
and responded. Group B included 18 patients who received more than two doses
of IVIG due to failure of the initial treatment. The mean duration of fever after initial
treatment in group B was significantly longer than it was in group A. In group B, we
found that higher bilirubin, aspartate aminotransferase (AST), polymorphonuclear
cells (PMN) (%), and lower platelet values at baseline were independent predic-
tors of persistent or recurrent fever in patients with KD. Coronary artery abnormali-
ties were found in 8 patients (44.4%) in group B and in two patients (6.1%) in group
A. We found that abnormal liver function tests and a lower platelet count at base-
line were possible predictors of nonresponders to IVIG in patients with KD. There
is a need for a prospective study focused on baseline hepatobiliary parameters.
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no return of fever (>37.8℃) for at least 7 days after IVIG,
with marked improvement or normalization of principal
clinical findings) (8, 9). Group A included 33 patients who
were admitted from January 2003 through April 2004. Group
B included 18 patients who received more than two doses
of IVIG due to failure of the initial treatment. This non-
response was defined as the return of fever and one or more
of the initial symptoms that led to the diagnosis of KD
within 2 to 7 days of treatment with IVIG (8, 9). Eighteen
patients who were admitted to our hospital between March
1995 and April 2004 were included in group B. We reviewed
the clinical characteristics of KD patients in groups A and
B, and we also analyzed laboratory parameters measured
before and after the use of IVIG in both groups.
Echocardiography
Two-dimensional echocardiography was performed at the
time of diagnosis. These tests were repeated approximately
at 1-2 weeks and at 7-10 weeks after diagnosis. Definitions
of coronary dilatation and aneurysm were based on published
criteria (11, 12): 1) a coronary artery luminal diameter of at
least 3 mm in a child <5 yr old, or at least 4 mm in a child
≥5 yr; 2) an internal diameter of a segment at least 1.5
times as large as that of an adjacent segment; or 3) a clearly
irregular lumen.
Data analysis
All data are expressed as means±standard deviation or as
percentages, as appropriate. The differences between the
two groups were assessed by using an unpaired t-test and
the Mann-Whitney U test, using SPSS 12.0 for Windows.
Values were considered significantly different at p<0.05.
RESULTS
A total of 51 patients were enrolled in our study. Of these
51, 34 (66.7%) were boys. There were 33 patients in group
A who received a single dose of IVIG, and 18 patients in
group B who required more than two doses of IVIG. In
group B, 4 patients did not initially respond and 14 others
had return of fever and symptoms (2-7 days after initial treat-
ment). Fifteen (83.3%) of the 18 patients in group B who
required the second dose of IVIG responded well. The remain-
ing 3 were treated with a third dose of IVIG and responded
fully. Clinical characteristics of both groups are presented in
Table 1. The mean duration of fever in group A was 10.36
±8.24 hr after initial treatment, whereas it was 120.72±
80.26 hr in group B. The mean duration of fever before ini-
tial treatment in group A was 150.91±79.41 hr, and in
group B it was 123.58±55.92 hr. As we expected, the mean
duration of fever after initial treatment in group B was sig-
nificantly longer than it was in group A. 
Laboratory results on admission for both groups are listed
in Table 2. There were no differences between the groups in
age, sex, hemoglobin, hematocrit, total leukocyte count, ery-
throcyte sedimentation rate (ESR), C-reactive protein (CRP),
total protein, albumin, alanine aminotransferase (ALT), or
the Harada score before IVIG treatment. Although the total
numbers of white blood cells (WBC) and hemoglobin values
were not different between groups, group B had a higher per-
centage of polymorphonuclear cells (PMN) (80.83±10.24%,
p=0.003), and a lower platelet count (326.67±100.68×103/
μ L, p=0.043) when compared with those (69.1±14.7%,
393.64±114.42×103/μ L, respectively) of group A. Group
B also had a higher serum total bilirubin level (2.75±2.13
*Data are the mean±standard deviation. 
NS, not significant. 
Group A (n=33) Group B (n=18)
p 
value
Sex (M:F) 22:11 12:6 NS
Age (month) 33.58±28.9 38.64±25.8 NS
Age <1 yr  8 (24.2%) 1 (5.6%)
Weight (kg)* 14.65±7.02 14.60±4.28 NS
Rash  31 (93.9%) 16 (88.9%) NS
Hands/feet edema  23 (69.7%) 11 (61.1%) NS
Cervical lymph node  25 (75.8%) 17 (94.4%) NS
Conjunctivitis  29 (87.9%) 18 (100%) NS
Oral lesion  29 (87.9%) 18 (100%) NS
Fever duration before 150.91±79.41 123.58±55.92 NS
initial treatment (hr)* 10.36±8.24 120.72±80.26 0.000
Fever duration after initial 
treatment (hr)*
Coronary artery lesion  2 (6.1%) 8 (44.4%)
Table 1. Clinical characteristics of KD patients on admission in
both group A and B
Data are the mean±standard deviation.
NS, not significant; Hct, hematocrit; PMN, polymorphonuclear cells;
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; AST,
aspartate aminotransferase; ALT, alanine aminotransferase.
Group A (n=33) Group B (n=18)
p 
value
Age (month) 33.58±28.9 38.64±25.8 NS
Hemoglobin (g/dL) 11.42±0.9 11.34±0.59 NS
Hct (%) 33.78±2.79 33.77±1.6 NS
Total leukocyte (×10
3/μ L) 15912±5725 13597±4773 NS
PMN (%) 69.1±14.7 80.83±10.24 0.003
Platelet (×10
3/μ L) 393.64±114.42 326.67±100.68 0.043
ESR (mm/hr) 47.97±12.22 45.47±13.6 NS
CRP (mg/dL) 5.86±1.02 5.99±1.66 NS
Total protein (g/dL) 6.29±0.52 6.48±0.79 NS
Albumin (g/dL) 3.32±0.52 3.27±0.53 NS
Total bilirubin (mg/dL) 0.53±0.25 2.75±2.13 0.000
direct bilirubin (mg/dL) 0.16±0.15 1.26±1.24 0.000
AST (IU/L) 65.45±81.44 138.59±165.81 0.027
ALT (IU/L) 79.70±87.97 175.71±176.94 NS
Harada score 4.24±1.268 4.33±0.985 NS
Table 2. Laboratory data on admission of both group A and B720 S. Cha, M. Yoon, Y. Ahn, et al.
mg/dL, p=0.000) when compared with that (1.26±1.24
mg/dL) of group A. Group B also had higher serum aspar-
tate aminotransferase (AST) values (138.59±165.81 IU/L,
p=0.027) when compared with that of group A (65.45±
81.44 IU/L). γ -glutamyl transpeptidase (γ -GTP) and lac-
tate dehydrogenase (LD) levels were excluded because the
data in group B were insufficient. In our retrospective series
of 18 patients in group B, we report that higher bilirubin,
AST, PMN (%), and lower platelet values at baseline are inde-
pendent predictors of persistent or recurrent fever in patients
with KD. Laboratory results from both groups usually 48 hr
after IVIG treatment are listed in Table 3. Contrary to the
laboratory results before IVIG treatment, there were no dif-
ferences between the groups in platelet count, AST, ALT,
and CRP after the IVIG treatment. After IVIG treatment,
group B had lower hemoglobin, higher total leukocyte counts,
higher percentages of PMN, higher ESRs, lower total pro-
tein and albumin levels, and higher bilirubin levels. Some-
what contrary to previous studies, it seems that in both groups
a higher percentage of PMN, lower platelet count, higher
bilirubin level, and higher AST value were associated with
the requirement for more than two doses of IVIG, before
IVIG was administered. The high platelet count, a charac-
teristic laboratory finding in KD, is not likely to be associ-
ated with additional IVIG treatment. Coronary artery abnor-
malities that developed during the acute phase and subacute
phase were found in 8 patients (44.4%) in group B and in
two patients (6.1%) in group A. In five of eight patients in
group B, the abnormality developed in the acute phase, and
in the other three it developed in the subacute phase. Six of
eight patients who had coronary artery abnormalities improv-
ed in the convalescent phase. The remaining one patient did
not receive a follow-up echocardiographic examination, and
another patient still had a coronary aneurysm. There were two
patients in group A who developed coronary artery aneurysms,
and both returned to normal in the convalescent phase. 
DISCUSSION
Since first reported in 1972, the number of cases of KD
has increased continuously, including two epidemics, and
thus KD is now recognized as an important and common
childhood illness in our country (13). The average incidence
of 86.4/100,000 children <5 yr old in South Korea is second
only to that of 134.2 in Japan (14).
In spite of the effectiveness of IVIG treatment in the acute
phase of KD (4, 5, 15), approximately 10-20% of patients
experience a persistent or recurrent fever despite initial IVIG
treatment (8, 9). Despite the use of standard IVIG regimens,
fever persists for more than 3 days after treatment in 20-30%
of children (5). These cases have been referred to as ‘‘nonre-
sponders to IVIG’’, or ‘‘initial treatment failure’’, or ‘‘IVIG
resistance’’, or ‘‘the re-treatment group’’ (4, 8, 15-20). A con-
sensus definition is needed for future studies. The patients
with persistent or recurrent fever could be at greatest risk of
developing coronary artery aneurysms. It is certain that the
febrile phase of the disease is significantly longer in children
with coronary aneurysms (21, 22). If we could identify the
factors related to patients with nonresponse to IVIG at admis-
sion, we could predict the need for subsequent re-treatment
or the risk of subsequent development of aneurysm. We found
that there were 18 patients who did not respond to initial
doses of IVIG. The average proportion of nonresponders to
IVIG in our study was 7.1% (2.2-11.5%) from 2001 to 2004.
This is comparable to the previous findings of Sundel et al.
(8) in 1993 (10%), Burns et al. (16) in 1998 (7.8%), Fuku-
nishi et al. (17) in 2000 (15.9%), and Durongpisitkul et al.
(18) in 2003 (11.6%). 
A multicenter, retrospective study (16) concluded that
persistent or recrudescent fever after the first course of IVIG
was associated with an increased risk of treatment failure.
The other definition of treatment failure, that of Wallace et
al. (19), is the return of fever and one or more of the initial
symptoms that led to the diagnosis of KD within 2 to 7 days
of treatment with IVIG. They do not mention the develop-
ment of coronary abnormalities. Coronary artery abnormali-
ties that developed during the acute phase and subacute
phase were found in eight patients (44.4%) among the non-
responders to IVIG (group B) and in two patients (6.1%)
among the responders to IVIG (group A). These percent-
ages are somewhat high compared with those in a previous
paper (19) that reported that nearly 23% of patients with
KD may require re-treatment and 8% may develop coro-
nary aneurysm. However, Hashino et al. (15) in 2001 report-
ed a high probability (48.6%) of developing coronary artery
Data are the mean±standard deviation.
IVIG, intravenous immunoglobulin; NS, not significant; Hct, hematocrit;
PMN, polymorphonuclear cells; ESR, erythrocyte sedimentation rate;
CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, ala-
nine aminotransferase.
Group A (n=33) Group B (n=18)
p 
value
Hemoglobin (g/dL) 10.94±1.14 10.38±1.16 0.031
Hct (%) 32.62±2.86 30.5±3.14 0.007
Total leukocyte (×10
3/μ L) 9562±3926 14188±5871 0.002
PMN (%) 41.72±18.92 58.68±21.84 0.008
Platelet (×10
3/μ L) 508.82±186.68 438.82±197.14 NS
ESR (mm/hr) 47.88±12.71 57.4±7.89 0.016
CRP (mg/dL) 6.29±6.12 10.08±7.90 NS
Total protein (g/dL) 7.95±0.91 7.23±0.62 0.037
Albumin (g/dL) 3.02±0.44 2.63±0.39 0.047
Total bilirubin (mg/dL) 0.28±0.15 1.17±1.62 0.018
Direct bilirubin (mg/dL) 0.10±0.09 0.61±0.91 0.020
AST (IU/L) 70.28±84.46 69.64±73.5 NS
ALT (IU/L) 66.28±62.68 90.45±66.19 NS
Table 3. Laboratory data after IVIG treatment of both group A
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lesions in IVIG nonresponders, and Fukunishi et al. (17) in
2000 reported that the incidence of coronary artery aneurysm
among nonresponders was 38.5%. There was no difference
in age, sex, duration of symptoms prior to treatment, initial
CRP, ESR, or the presence of an abnormal initial echocar-
diogram between initial responders and nonresponders (18,
19, 21). These findings are somewhat similar to our results
in that there were no significant differences in age, sex, body-
weight, and duration of fever before administration of IVIG
between responders and nonresponders to IVIG. It is a nat-
ural result that the duration of fever after the initial IVIG
administration was much longer in the nonresponding group
than in the responding group. An interesting finding, which
we did not analyze statistically, was the unusually high occur-
rence (94.4%) of cervical lymph node enlargement in the
nonresponding group in spite of the fact that cervical lym-
phadenitis is the least common of the principal clinical fea-
tures of KD.
We report that a higher bilirubin level, higher AST level,
higher percentage of PMN, and a lower platelet count those
that of the responding group at baseline were all independent
predictors of persistent or recurrent fever in patients with
KD. These patients could be given more IVIG. After IVIG
treatment, group B had lower hemoglobin, higher total leuko-
cyte counts, higher percentages of PMN, higher ESRs, lower
total protein and albumin levels, and higher bilirubin levels.
These significant differences in group B could be related to
the suggestion of additional risk findings of the occurrence of
coronary artery lesions. Many authors (4, 18, 23) have agreed
that increased white blood cell and neutrophil counts and
increased CRP concentration after IVIG treatment are risk
factors for coronary artery lesions. However, we found no
association of CRP concentration, which measured at admis-
sion and usually 48 hr after IVIG treatment, with failure of
initial IVIG treatment. These results maybe associated with
shorter febrile days before IVIG treatment compared with
previous papers (17, 18, 29, 30) because of more or less low
CRP levels. We found also no correlation between age, gen-
der, and days since starting IVIG treatment, with failure of
the initial IVIG treatment.
In the present study, a lower platelet count in the nonre-
sponding group at baseline was an independent predictor of
persistent or recurrent fever with possible coronary compli-
cations. Burns et al. (24) explained that the reason thrombo-
cytopenia is associated with KD is that the increased platelet
turnover occurs during the activation of coagulation in the
early phase of the disease. Other parameters of anemia, left
shift, and low platelet count secondary to increased platelet
turnover presumably reflect increased release of inflamma-
tory mediators and worsened vascular inflammation (25, 26).
Fukunishi et al. (17) first reported that biliary tract-associ-
ated parameters such as total bilirubin and γ -GTP, which
probably reflect inflammation of the bile duct, were not pre-
viously found to be associated with a high risk for develop-
ment of coronary artery lesions. Also, the levels of AST/ALT
were higher in nonresponders, but this was not clinically sta-
tistically significant. We had similar results in regard to base-
line hepatobiliary parameters. Although we did not exam-
ine γ -GTP and lactate dehydrogenase levels, we found sig-
nificantly elevated serum AST activity, and elevated direct
and total bilirubin levels in the nonresponding group at the
baseline examination. We found that serum ALT was elevat-
ed, but this difference was not statistically significant. Serum
ALT activity was elevated in approximately one-third of KD
patients, and 18% had levels exceeding 100 U/L. A case-com-
parison study (27) reported that elevated serum ALT activi-
ty was much more frequently observed at the time of initial
evaluation and diagnosis of KD. 
A nationwide epidemiologic study in Japan (28) demon-
strated a relationship between the level of serum transami-
nase and the development of cardiac disorders. The eleva-
tion of the ALT in KD patients is associated with the devel-
opment of cardiac disorders. The proportion of those with-
out cardiac disorders with an ALT of 50 IU/I or more was
36%. An ALT of 50 IU/I or more was noted in 49% of the
patients with transient cardiac conditions and 52% of those
with persistent cardiac disorders. It was proved that the ele-
vation of the serum ALT at the initial examination was related
to the complications of both transient and persistent cardiac
disorders.
In conclusion, we found that a higher bilirubin level, higher
AST level, higher percentage of PMN, and lower platelet
count than those of the responder group at baseline were inde-
pendent predictors of persistent or recurrent fever in patients
with KD. The patients who did not respond to initial IVIG
treatment had a higher probability (44.4%) of developing
coronary artery abnormalities. The optimal re-treatment dose
of IVIG and treatment guidelines should be determined for
this small group of nonresponders to IVIG. There is a need for
a prospective study focused on baseline hepatobiliary param-
eters.
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